Moderate lifetime marijuana smoking not associated with lung function decline
the ONA take:
According to a new study published online in the journal Annals of the American Thoracic Society, researchers at Emory University in Atlanta, Georgia, have found that moderate lifetime marijuana use is associated with airway inflammation, but not significant changes in lung function.
For the study, researchers analyzed data from the National Health and Nutrition Examination Survey (NHANES). They identified over 5,000 adult survey participants with data on recent marijuana use and respiratory symptoms. Results showed that nearly 60% reported using marijuana at least once during their lifetime, and about 12% said they had used marijuana in the last month.
Among the 3,000 adult participants who had patterns of lifetime marijuana use, cumulative exposure of less than 20 joint-years was not linked with significant changes in lung function; however, more than 20 joint-years of marijuana exposure was associated with clinically significant changes in lung function.
The results do not show whether this change in lung function represents early lung function decline like that of long-term tobacco use. Researchers also found that marijuana smoking increased respiratory irritation, but the study could not determine whether those symptoms were permanent.
The researchers note that they did not assess an association between marijuana use and cancer.
Moderate lifetime marijuana use is associated with airway inflammation, but not significant changes in lung function.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|